A detailed history of Greenleaf Trust transactions in Repligen Corp stock. As of the latest transaction made, Greenleaf Trust holds 1,516 shares of RGEN stock, worth $227,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,516
Holding current value
$227,248
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$119.79 - $167.35 $181,601 - $253,702
1,516 New
1,516 $225,000
Q1 2024

Apr 29, 2024

BUY
$170.78 - $208.42 $9,051 - $11,046
53 Added 4.03%
1,369 $251,000
Q4 2023

Jan 31, 2024

SELL
$114.17 - $185.35 $64,734 - $105,093
-567 Reduced 30.11%
1,316 $236,000
Q3 2023

Nov 09, 2023

SELL
$138.78 - $176.51 $5,134 - $6,530
-37 Reduced 1.93%
1,883 $299,000
Q2 2023

Aug 09, 2023

BUY
$138.42 - $180.31 $59,797 - $77,893
432 Added 29.03%
1,920 $271,000
Q1 2023

May 11, 2023

BUY
$154.26 - $198.1 $15,734 - $20,206
102 Added 7.36%
1,488 $250,000
Q4 2022

Jan 25, 2023

SELL
$162.42 - $220.56 $13,805 - $18,747
-85 Reduced 5.78%
1,386 $235,000
Q3 2022

Nov 10, 2022

BUY
$160.42 - $256.21 $6,577 - $10,504
41 Added 2.87%
1,471 $275,000
Q2 2022

Aug 12, 2022

SELL
$140.68 - $188.02 $20,257 - $27,074
-144 Reduced 9.15%
1,430 $232,000
Q1 2022

Apr 27, 2022

SELL
$161.19 - $257.96 $10,799 - $17,283
-67 Reduced 4.08%
1,574 $296,000
Q4 2021

Feb 11, 2022

BUY
$247.59 - $304.47 $64,620 - $79,466
261 Added 18.91%
1,641 $435,000
Q3 2021

Nov 12, 2021

BUY
$194.77 - $324.21 $10,712 - $17,831
55 Added 4.15%
1,380 $399,000
Q2 2021

Aug 10, 2021

SELL
$165.87 - $220.95 $3,649 - $4,860
-22 Reduced 1.63%
1,325 $264,000
Q1 2021

Apr 30, 2021

BUY
$180.37 - $226.26 $12,625 - $15,838
70 Added 5.48%
1,347 $262,000
Q4 2020

Feb 08, 2021

BUY
$148.08 - $206.57 $189,098 - $263,789
1,277 New
1,277 $245,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $8.32B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Greenleaf Trust Portfolio

Follow Greenleaf Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenleaf Trust, based on Form 13F filings with the SEC.

News

Stay updated on Greenleaf Trust with notifications on news.